C. Diff News and Research

RSS

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences.

6 Oct 2014

C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

C Diff Foundation is proud to present the 2014 "Raising C.difficile Awareness" conference. Join us November 4th at 8 a.m. – 5 p.m. at the University of Illinois at Chicago, Student Center, West 828 S. Wolcott Avenue, Thompson Room, Chicago, IL.

23 Sep 2014

University of Leicester research sniffs out smell of disease in feces

A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria C. diff, that causes diarrhoea, temperature and stomach cramps, has been developed by a team at the University of Leicester.

1 Sep 2014

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative.

10 Jul 2014

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Wheaton Franciscan Healthcare-Iowa is the latest to deploy TRU-D SmartUVC, a 5-foot-5 germ-killing ultraviolet robot equipped with the only infection prevention data collection and reporting software on the market. TRU-D is now in use at Covenant Medical Center in Waterloo and Sartori Medical Center in Cedar Falls, Iowa.

30 Jun 2014

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)

30 Jun 2014

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex Disinfection Services, the world leader in UV room disinfection systems, testified yesterday before the U.S. House of Representatives Committee on Science, Space, and Technology; Subcommittee on Research and Technology; and Subcommittee on Oversight.

28 Jun 2014

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher.

17 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

TeleTracking’s hand hygiene technology redefines infection prevention standards at New Cross Hospital

New Cross Hospital, part of The Royal Wolverhampton NHS Trust, today announced a milestone of one million hand hygiene observations using TeleTracking Technologies, Inc.'s automated hand hygiene sensor as part of the 'Safe Hands' program.

9 Jun 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Da Volterra presents promising results of DAV-132 compound for prevention of severe C. diff infections

Da Volterra, a leading biopharmaceutical company in the field of bacterial resistance, announces today very promising new results about DAV132 in the prevention of the side effects of antibiotics and the occurrence of severe Clostridium difficile infections.

13 May 2014

Luminex announces group B strep as fifth assay planned for launch menu of ARIES

Luminex Corporation today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™.

From Luminex 12 May 2014

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

In the United States, approximately 179 million cases of acute diarrhea occur each year, and most of those cases are entirely preventable, a researcher from The University of Texas Health Science Center at Houston concluded in a New England Journal of Medicine review article.

23 Apr 2014

Daylight Medical releases SKY 6Xi disinfection technology for mobile devices

Daylight Medical, manufacturer and provider of innovative medical products, is pleased to announce its rollout of SKY 6Xi, disinfection technology for mobile devices. SKY 6Xi uses high intensity (254 nanometer wavelength) ultraviolet light in the "C" spectrum (UVC) at close proximity to thoroughly disinfect a mobile device. The unique power of SKY reduces the risk that Hospital-acquired infections (HAIs) are transmitted to patients while improving safety for healthcare workers.

15 Apr 2014

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

31 Jan 2014

New comprehensive edition for neurologists provides invaluable source of reference

A new comprehensive edition of a standard work, detailing and illustrating the organization, structure, function and connectivity of all individual brainstem nuclei. For neuroscientists and neurologists this atlas provides an invaluable and complete source of reference for both their scientific research and everyday clinical practice.

17 Dec 2013

Government spending cuts within NHS increase risk of Clostridium difficile infection

72% of clinicians believe that Government spending cuts within the NHS increase the risk of hospital acquired infections. The ‘Think C-differently’ report, which advises on the current Clostridium difficile landscape, found that despite stringent measures to manage and control Clostridium difficile infection, the NHS is still battling to keep infection rates to a minimum.

8 Nov 2013

American Dryer unveils new product with Cold Plasma Clean technology

American Dryer recently unveiled a new product that incorporates cold plasma, a natural occurring phenomenon, into its market-leading hand dryers.

6 Nov 2013

Swallowing pills containing fecal bacteria stops recurrent bouts of C. diff infection

Swallowing pills containing a concentrate of fecal bacteria successfully stops recurrent bouts of debilitating Clostridium difficile (C. diff) infection by rebalancing the bacteria in the gut, suggests a study being presented at the IDWeek 2013- meeting today.

5 Oct 2013